Patient compliance and the conduct and interpretation of therapeutic trials
- 作者R.Brian Haynes; Renato Dantes
- 卷第8卷
- 期第1期
- 文件大小523.16KB
- 发表时间1987
- DOI10.1016/0197-2456(87)90021-3
- 页码12-19
Surrogate endpoint use in cardiovascular clinical trialsJ.L. Probstfield; S. Yusuf; L.M. Friedman; D.R. Labarthe; J.D. Bristow; J. Wittes · 1986
Healthy eating and reduced risk of cognitive decline: A cohort from 40 countriesSmyth, A.; Dehghan, M.; O'Donnell, M.; Anderson, C.; Teo, K.; Gao, P.; Sleight, P.; Dagenais, G.; Probstfield, J. L.; Mente, A.; Yusuf, S. · Neurology · 2015
At what level should LDL-cholesterol be reduced for secondary prevention? Rationale and design of the NIH Post-CABG clinical trialL. Campeau; D.B. Hunninghake; J.A. Herd; G. Knatterud; J.L. Probstfield; S. Yusuf; J.S. Forrester; I. Goldenberg; B. Hoogwerf; C. White; M. Domanski; J. Davignon; NIH Post-CABG Clinical Trial Investigators · 1994
Relationship Between Healthy Diet and Risk of Cardiovascular Disease Among Patients on Drug Therapies for Secondary Prevention: A Prospective Cohort Study of 31 546 High-Risk Individuals From 40 CountriesDehghan, M.; Mente, A.; Teo, K. K.; Gao, P.; Sleight, P.; Dagenais, G.; Avezum, A.; Probstfield, J. L.; Dans, T.; Yusuf, S. · Circulation · 2012
Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) TrialsBohm, M.; Baumhakel, M.; Teo, K.; Sleight, P.; Probstfield, J.; Gao, P.; Mann, J. F.; Diaz, R.; Dagenais, G. R.; Jennings, G. L. R.; Liu, L.; Jansky, P.; Yusuf, S. · Circulation · 2010